HIV and travel

Travel Medicine and Infectious Disease

Volumn 4, Issue 3-4, 2006, Pages 174-183

  Schuhwerk, M A ^a   Richens, J ^a,b   Zuckerman, Jane N ^c  

^a Camden Primary Care Trust   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Entry restrictions; HIV; Stigmatisation; Travel; Vaccinations

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; ANTIDIARRHEAL AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTIMALARIAL AGENT; ANTIRETROVIRUS AGENT; BCG VACCINE; CHOLERA VACCINE; CLOTRIMAZOLE; DIPHTHERIA VACCINE; DOXYCYCLINE; FLUCONAZOLE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE; JAPANESE ENCEPHALITIS VACCINE; LIVE VACCINE; LOPERAMIDE; MEASLES VACCINE; MENINGITIS VACCINE; ORAL POLIOMYELITIS VACCINE; PNEUMOCOCCUS VACCINE; RABIES VACCINE; TETANUS TOXOID; TUBERCULOSTATIC AGENT; TYPHOID VACCINE; UNINDEXED DRUG; YELLOW FEVER VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CD4 LYMPHOCYTE COUNT; CHOLERA; CLINICAL FEATURE; CLINICAL TRIAL; CONFIDENTIALITY; DIPHTHERIA; DISEASE ASSOCIATION; DISEASE COURSE; DRUG ALCOHOL INTERACTION; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG EXCRETION; DRUG FATALITY; DRUG SAFETY; EPIDEMIC ENCEPHALITIS; HEALTH CARE POLICY; HEALTH INSURANCE; HEALTH STATUS; HEPATITIS A; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; INFECTION PREVENTION; INFECTION RISK; INFLUENZA; INFORMATION DISSEMINATION; INTERNET; LUNG TUBERCULOSIS; MALARIA; MEASLES; MEDICAL INFORMATION; MENINGITIS; MYCOSIS; NONHUMAN; ORAL REHYDRATION THERAPY; PARALYSIS; PATIENT COMPLIANCE; PATIENT INFORMATION; PHOTOSENSITIVITY; POLIOMYELITIS; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; RABIES; SAFE SEX; SAFETY; SKIN ALLERGY; STREPTOCOCCUS INFECTION; SUPERINFECTION; TETANUS; TRAVEL; TRAVELLER DIARRHEA; TYPHOID FEVER; URINARY EXCRETION; VIRUS LOAD; VIRUS REACTIVATION; VIRUS TRANSMISSION; VIRUS VIRULENCE; YELLOW FEVER;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; COUNSELING; HIV INFECTIONS; HUMANS; PRIMARY PREVENTION; STEREOTYPING; TRAVEL; VACCINATION;

EID: 33646385109     PISSN: 14778939     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tmaid.2005.06.012     Document Type: Article

References (38)

1. Kemper C.A., Linett A., Kane C., and Deresinski S.C. Frequency of travel of adults infected with HIV. J Travel Med 2 2 (1995) 85-88
2. Simons F.M., Cobelens F.G., and Danner S.A. Common health problems in HIV-infected travelers to the (sub)tropics. J Travel Med 6 2 (1999) 71-75
3. Breuer-McHam J., Simpson E., Dougherty I., Bonkobara M., Ariizumi K., Lewis D.E., et al. Activation of HIV in human skin by ultraviolet B radiation and its inhibition by NFkappaB blocking agents. Photochem Photobiol 74 6 (2001) 805-810
4. Jost S., Bernard M.C., Kaiser L., Yerly S., Hirschel B., Samri A., et al. A patient with HIV-1 superinfection. N Engl J Med 347 10 (2002) 731-736
5. Leggat P.A., Carne J., and Kedjarune U. Travel insurance and health. J Travel Med 6 4 (1999) 243-248
6. Ponnusamy K, Lambert N, Perry N, Johnson D, Churchill DR. XXXX patients on HAART travelling the USA-what do they do? In: European AIDS conference (EACS), Warsaw, October 2003.
7. French N., Nakiyingi J., Carpenter L.M., Lugada E., Watera C., Moi K., et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 355 9221 (2000) 2106-2111
8. Klugman K.P., Madhi S.A., Huebner R.E., Kohberger R., Mbelle N., and Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 349 14 (2003) 1341-1348
9. Castelli F., and Patroni A. The human immunodeficiency virus-infected traveler. Clin Infect Dis 31 6 (2000) 1403-1408
10. Talbot E.A., Perkins M.D., Silva S.F., and Frothingham R. Disseminated bacille Calmette-Guerin disease after vaccination: case report and review. Clin Infect Dis 24 6 (1997) 1139-1146
11. Kengsakul K., Sathirapongsasuti K., and Punyagupta S. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thai 85 1 (2002) 131-134
12. MMWR Morbidity Mortality Weekly Report. Measles pneumonitis following measles-mumps-rubella vaccination of a patient with HIV infection, 1993. MMWR Morb Mortal Wkly Rep 45 28 (1996) 603-606
13. Castelli F.P.C. The traveler with HIV. In: Keystone Y.K.P.F.D. (Ed). Travel medicine (2004), Mosby 257-267
14. Willis E., and Sherrod J.L. Childhood immunizations: position on the enhanced inactivated poliovirus vaccine and live attenuated oral poliovirus vaccine dilemma. J Natl Med Assoc 89 12 (1997) 785-789
15. Chitsike I., and van Furth R. Paralytic poliomyelitis associated with live oral poliomyelitis vaccine in child with HIV infection in Zimbabwe: case report. BMJ 318 7187 (1999) 841-843
16. Ion-Nedelcu N., Dobrescu A., Strebel P.M., and Sutter R.W. Vaccine-associated paralytic poliomyelitis and HIV infection. Lancet 343 8888 (1994) 51-52
17. Nkowane B.M., Wassilak S.G., Orenstein W.A., Bart K.J., Schonberger L.B., Hinman A.R., et al. Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984. JAMA 257 10 (1987) 1335-1340
18. Tayal S.C., and Sankar K.N. Impaired response to recombinant hepatitis B vaccine in asymptomatic HIV-infected individuals. AIDS 8 4 (1994) 558-559
19. Witt D.J., Craven D.E., and McCabe W.R. Bacterial infections in adult patients with the acquired immune deficiency syndrome (AIDS) and AIDS-related complex. Am J Med 82 5 (1987) 900-906
20. Redd S.C., Rutherford III G.W., Sande M.A., Lifson A.R., Hadley W.K., Facklam R.R., et al. The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents. J Infect Dis 162 5 (1990) 1012-1017
21. Rousseau M.C., Moreau J., and Delmont J. Vaccination and HIV: a review of the literature. Vaccine 18 9-10 (1999) 825-831
22. Ockenga J., Tillmann H.L., Trautwein C., Stoll M., Manns M.P., and Schmidt R.E. Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. J Hepatol 27 1 (1997) 18-24
23. Thurn J.R., and Henry K. Influenza A pneumonitis in a patient infected with the human immunodeficiency virus (HIV). Chest 95 4 (1989) 807-810
24. Fuller J.D., Craven D.E., Steger K.A., Cox N., Heeren T.C., and Chernoff D. Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: impact on plasma levels of HIV type 1 RNA and determinants of antibody response. Clin Infect Dis 28 3 (1999) 541-547
25. Puri A., Riley J.L., Kim D., Ritchey D.W., Hug P., Jernigan K., et al. Influenza virus upregulates CXCR4 expression in CD4+ cells. AIDS Res Hum Retroviruses 16 1 (2000) 19-25
26. Goujon C, Thor M, Feuille V, Coulaud JP, Dupont B, San-Sonetti P. Good tolerance and efficacy of yellow fever vaccine among carriers of human immunodeficiency virus. In: Fourth international conference on travel medicine, Acapulco, Mexico, 1995.
27. Muller O., and Moser R. The clinical and parasitological presentation of Plasmodium falciparum malaria in Uganda is unaffected by HIV-1 infection. Trans R Soc Trop Med Hyg 84 3 (1990) 336-338
28. Bloland P.B., Wirima J.J., Steketee R.W., Chilima B., Hightower A., and Breman J.G. Maternal HIV infection and infant mortality in Malawi: evidence for increased mortality due to placental malaria infection. AIDS 9 7 (1995) 721-726
29. French N., Nakiyingi J., Lugada E., Watera C., Whitworth J.A., and Gilks C.F. Increasing rates of malarial fever with deteriorating immune status in HIV-1-infected Ugandan adults. AIDS 15 7 (2001) 899-906
30. Grimwade K., French N., Mbatha D.D., Zungu D.D., Dedicoat M., and Gilks C.F. Childhood malaria in a region of unstable transmission and high human immunodeficiency virus prevalence. Pediatr Infect Dis J 22 12 (2003) 1057-1063
31. Whitworth J., Morgan D., Quigley M., Smith A., Mayanja B., Eotu H., et al. Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study. Lancet 356 9235 (2000) 1051-1056
32. Wilson M.E., von Reyn C.F., and Fineberg H.V. Infections in HIV-infected travelers: risks and prevention. Ann Intern Med 114 7 (1991) 582-592
33. Ruff T, O'Brien D. In: Crowe S, Hoy J, Mills J, editors. Management of the HIV-infected patient, 2nd ed. Dunitz; 2002. p. 601-18.
34. Kemper C.A., Linett A., Kane C., and Deresinski S.C. Travels with HIV: the compliance and health of HIV-infected adults who travel. Int J STD AIDS 8 1 (1997) 44-49
35. NNRTI and PI Drug Interactions. The University of Liverpool, 2004.
36. Khaliq Y., Gallicano K., Tisdale C., Carignan G., Cooper C., and McCarthy A. Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers. Br J Clin Pharmacol 51 6 (2001) 591-600
37. Schippers E.F., Hugen P.W., den Hartigh J., Burger D.M., Hoetelmans R.M., Visser L.G., et al. No drug-drug interaction between nelfinavir or indinavir and mefloquine in HIV-1-infected patients. AIDS 14 17 (2000) 2794-2795
38. Karp CL. Prophylaxis and treatment of malaria in the presence of HIV protease inhibitor therapy, 2004.